indazoles has been researched along with Thyroid Cancer, Anaplastic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, E; Bell, AC; Fan, D; Ganly, I; Groen, AH; Kang, JJ; Lee, NY; Leeman, JE; Lok, BH; Ma, J; McBride, S; Olsen, KS; Riaz, N; Shaha, AR; Sherman, EJ; Tsai, CJ | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ | 1 |
| Bible, KC; Bieber, C; Bossou, AR; Burton, JK; Erlichman, C; Goh, BC; Harris, P; Isham, CR; Karlin, NJ; Kukla, AK; Kumar, P; Lim, WT; Maples, WJ; Menefee, ME; Molina, JR; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Bible, KC; Bossou, AR; Copland, JA; Fisher, KE; Isham, CR; Kumar, R; Lingle, WL; Marlow, L; Negron, V; Sherman, EJ; Smallridge, RC; Suman, VJ | 1 |
1 trial(s) available for indazoles and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer.
Topics: Aged; Animals; Disease Progression; Disease-Free Survival; Endpoint Determination; Female; Humans; Indazoles; Male; Mice; Mice, Nude; Middle Aged; Pyrimidines; Sulfonamides; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2012 |
3 other study(ies) available for indazoles and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Dose-Response Relationship, Radiation; Doxorubicin; Female; Follow-Up Studies; Humans; Indazoles; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Thyroidectomy; Tumor Burden | 2020 |
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycine; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Vorinostat | 2016 |
Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Sulfonamides; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Tubulin Modulators | 2013 |